Is stiripentol truly effective for treating primary hyperoxaluria?

  1. Hoppe, Bernd 1
  2. Feldkötter, Markus 2
  3. Martin-Higueras, Cristina 13
  1. 1 Department of Pediatrics, Division of Pediatric Nephrology, University Children’s Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany
  2. 2 Department of Pediatrics, Division of Pediatric Nephrology, University Children’s Hospital Zurich, Zurich, Switzerland
  3. 3 Institute of Experimental Immunology, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany
  4. 4 Universidad de La Laguna
    info

    Universidad de La Laguna

    San Cristobal de La Laguna, España

    ROR https://ror.org/01r9z8p25

Montrer des affiliations +
Revue:
Clinical Kidney Journal

ISSN: 2048-8513

Année de publication: 2020

Volumen: 14

Número: 1

Pages: 442-444

Type: Article

DOI: 10.1093/CKJ/SFAA068 GOOGLE SCHOLAR lock_openAccès ouvert editor

D'autres publications dans: Clinical Kidney Journal

Objectifs de Développement Durable

Références bibliographiques

  • Weigert A, Martin-Higueras C, Hoppe B. Novel therapeutic approaches in primary hyperoxaluria. Expert Opin Emerg Drugs 2018; 23: 349–357
  • Wyatt CM, Dru¨ eke TB. Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int 2020;97:17–19.
  • Le Dudal M, Huguet L, Perez J et al. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J Clin Invest 2019; 129: 2571–2577
  • Brigo F, Igwe SC, Bragazzi NL. Stiripentol add-on therapy for focal refractory epilepsy. Cochrane Database Syst Rev 2018; 5: CD009887
  • Hoppe B, Cochat P, Lemoine S et al. PHYOX: a safety and tolerability study of DCR-PHXC in primary hyperoxaluria types 1 and 2. Poster TH-PO449. Presented at the American Society of Nephrology Kidney Week 2019, Washington, DC.